Placebo + Reldesemtiv 150 mg + Reldesemtiv 450 mg
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Spinal Muscular Atrophy
Conditions
Spinal Muscular Atrophy
Trial Timeline
Jan 14, 2016 → May 31, 2018
NCT ID
NCT02644668About Placebo + Reldesemtiv 150 mg + Reldesemtiv 450 mg
Placebo + Reldesemtiv 150 mg + Reldesemtiv 450 mg is a phase 2 stage product being developed by Astellas Pharma for Spinal Muscular Atrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT02644668. Target conditions include Spinal Muscular Atrophy.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02644668 | Phase 2 | Completed |
Competing Products
20 competing products in Spinal Muscular Atrophy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SUN13837 injection + Placebo | Daiichi Sankyo | Phase 2 | 52 |
| Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells | Sun Pharmaceutical | Phase 2 | 52 |
| Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells | Sun Pharmaceutical | Phase 1 | 33 |
| Elezanumab | AbbVie | Pre-clinical | 23 |
| Elezanumab + Placebo | AbbVie | Phase 2 | 52 |
| Ropivacaine + Bupivacaine | AstraZeneca | Phase 3 | 77 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 1 | 33 |
| Zolgensma | Novartis | Pre-clinical | 23 |
| BVS857 + Placebo | Novartis | Phase 2 | 52 |
| AVXS-101 | Novartis | Phase 1 | 33 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 3 | 77 |
| Onasemnogene Abeparvovec-brve | Novartis | Approved | 85 |
| Onasemnogene Abeparvovec-xioi | Novartis | Pre-clinical | 23 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 3 | 77 |
| branaplam | Novartis | Phase 1/2 | 41 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 3 | 77 |
| onasemnogene abeparvovec | Novartis | Phase 3 | 77 |
| onasemnogene abeparvovec-xioi | Novartis | Phase 3 | 77 |
| Risdiplam | Roche | Phase 1 | 33 |
| ATI355 | Novartis | Phase 1 | 33 |